Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
See the moon shine with Saturn in the southern sky after sunset Dec. 26 - 2France will build a new aircraft carrier as it increases defense spending
- 3Whale stranded off Germany for days found stuck again
- 4A Sweet Choice: Pick Your #1 Cake!
- 5Vote In favor of Your Favored Video Conferencing Administration
- The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- Saudi Arabia says it intercepted 7 missiles, debris falls near energy facilities
- Vote In favor of Your Favored Kind Of Attire
- Zelensky sees win for Ukraine as EU finally reaches funding deal
- Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
- Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
- Most loved Road Food: Which One Prevails upon You?
- Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
